Clorox (NYSE:CLX) is currently offering a dividend yield of 5.15%, supported by an annualized payout of $4.96 per share. However, the dividend is backed by only a modest earnings buffer, with initial estimates indicating that the payout represents roughly 102% of the company's fiscal 2026 GAAP guidance midpoint. This narrow coverage has drawn attention from income-focused investors, particularly as the company's shares ended Friday at $96.32, down 2.4% on the day and 0.2% lower for the week.
The payout ratio calculation is based on guidance rather than full-year reported results. When adjusted for certain expenses—such as acquisition and digital investment costs—the ratio improves to approximately 89%. The 12-percentage-point gap highlights the impact of non-recurring items, including an estimated 90-cent ERP shipment reversal that affects both reported and adjusted figures. This discrepancy is significant for income investors assessing the sustainability of the dividend.
Clorox's reported earnings margin remains narrow, and even the adjusted margin is limited. The company's guidance accounts for 30 cents in GOJO transaction expenses and 37 cents tied to digital and productivity investments, which are excluded from adjusted guidance. Meanwhile, the 90-cent ERP reversal remains included in both metrics. These factors complicate a clear assessment of the company's ongoing dividend capacity.
On Friday, Clorox shares underperformed the broader market, with the S&P 500 falling 1.01%. The decline wiped out nearly all gains from the previous two sessions. The stock now trades 27.05% below its 52-week high of $132.00 set on July 23, 2025. Trading volume reached 2.37 million shares, below the 50-day average, indicating relatively subdued activity.
Compared to peers, Clorox appears attractively valued on a price-to-earnings basis. The company trades at a trailing P/E of 15.65, a 29% discount to the sector median of 21.94. Its dividend yield of 5.15% is 225 basis points higher than the median of 2.90% among comparable companies. However, the lower GAAP coverage raises questions about the sustainability of this yield.
Analyst sentiment remains cautious. On Thursday, UBS raised its price target on Clorox to $100 from $96, maintaining a Neutral rating, while JPMorgan lowered its target to $92 from $95, keeping an Underweight rating. Overall, the stock has three Buy ratings, 14 Holds, and four Sells. The median price target of $97 implies a potential upside of just 0.7% from current levels.
Clorox's guidance for fiscal 2026 reflects a challenging environment. The company projects net sales to decline approximately 6%, with organic sales falling about 9%. Gross margin is expected to contract by 250 to 300 basis points. The company cited energy costs as a margin headwind. In the third quarter, Clorox reported steady sales of $1.67 billion and adjusted earnings growth of 13% to $1.64 per share. CEO Linda Rendle described the performance as "mixed," noting "there is more work to do."
Cash generation has also weakened. Nine-month operating cash flow dropped 59% to $282 million, primarily due to a Glad venture termination payment. This decline further complicates the assessment of dividend sustainability. The company is scheduled to report its next earnings on August 3 after the market close, with a management webcast for analysts at 5:00 p.m. ET.
Risks to the dividend include weaker demand, rising energy expenses, and costs related to the GOJO integration. On the positive side, stronger execution or reduced input costs could improve coverage. The upcoming earnings report on August 3 will provide critical insight into whether the earnings cushion is beginning to recover.
